Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lmao people who sell premarket right before a stock takes off crack me up $SELB
Game time tomorrow, get the Cuban cigars ready $SELB
Wowza. Something coming imo
Moving nicely in A/H’s now, wow big buys $SBEL
Even better after market.
Beautiful move today much more to come for sure!!! $SELB
Nice EOD volume and increase in PPS
$SELB NHOD into the close? Seems like we can
Wackaroonies took it to the $2.60 intraday support let’s see if they run it up past HOD again $SELB
Just stickied some massive DD tons of info!!! $SELB
Phase 2 head-to-head (COMPARE) clinical trial of SEL-212 vs. KRYSTEXXA® to begin in 1Q19, interim six-month data expected in 4Q19.
Collaboration with CureCN projected to dose first patient with combination of ImmTOR + AAV gene therapy candidate in 2H19
Company raised $33M in gross offering proceeds and $31.3M in net proceeds in 1Q19, cash runway into 1Q20.
New CEO Dr. Carsten Brunn worked at Bayer for 8 years, Bausch & Lomb for a year and Novartis for 3 years.
He received his Ph.D in Chemistry from the University of Hamburg
“During 2018 we laid a strong groundwork for a year of execution in 2019. We kicked off the year by streamlining the company through a corporate restructuring, which is projected to cut our cash burn rate by 19%. We then completed an equity fund-raise of approximately $33 million in gross proceeds and $31.3 million in net proceeds, and anticipate reporting key milestones for both our chronic refractory gout and gene therapy programs.
We continue to believe that our lead program, SEL-212, has the
potential to address several unmet needs in chronic refractory gout patients, including sustained serum uric acid reduction, reduced painful flares and once monthly dosing, and we look forward to initiating
the planned six-month head-to-head (COMPARE) clinical trial against Krystexxa this month,” said Carsten Brunn, Ph.D., President and CEO of Selecta.
“We also look forward to further advancing our ImmTOR +
AAV gene therapy combination product candidate in Crigler-Najjar Syndrome in collaboration with CureCN in the second half of the year and identifying other ways to advance our ImmTOR platform and
grow our strategic partnerships.”
Effective December 1, 2018, Carsten Brunn, Ph.D., assumed
the role of President and CEO of Selecta, following his previous position as President of Pharmaceuticals for the Americas Region and member of the Global Pharmaceutical Executive Committee at Bayer.
Reported Phase 2 Data: Selecta has reported data from its Phase 2 trial showing that 66% of evaluable patients (21/32), maintained serum uric acid (sUA) levels of <6mg/dL after five oncemonthly treatments of SEL-212 at doses of 0.1 or 0.15 mg/kg of ImmTOR in combination with 0.2mg/kg of pegadricase. Furthermore, reduced total urate burden and lowered flare rates and severity were observed in the Phase 2 clinical trial, and SEL-212 continued to be generally well tolerated.
Collaboration with CureCN Consortium Projected to Dose First Patient in 2H19. In September 2018, Selecta announced a collaboration with CureCN, a European consortium, for an ImmTOR+AAV gene therapy combination product candidate in Crigler-Najjar Syndrome, building upon pre-clinical work that was published together with Genethon in Nature Communications in October 2018. Selecta expects CureCN to initiate preclinical toxicology studies in the first half of 2019 and for the combination product candidate to enter the clinic in the second half of 2019.
Selecta expects to initiate a Phase 2 head-to-head (COMPARE) clinical trial of SEL-212, compared to the current FDA-approved uricase therapy, Krystexxa, in the first quarter of 2019. An interim six-month data readout is projected for the fourth quarter of 2019, with a full statistical data analysis expected in the first quarter of 2020. The results of the COMPARE trial are expected to inform the design of the planned Phase 3 clinical trial of SEL-212, which the company plans to initiate in the fourth quarter of 2019.
Cash Position: Selecta had $37.7 million in cash, cash equivalents and restricted cash as of December 31, 2018, which compares to cash, cash equivalents and short-term investments of $50.5 million at
September 30, 2018. The company currently has a cash runway into the first quarter of 2020, which includes proceeds net of underwriting discounts and commissions of $31.3 million from the company’s recent follow-on offering in January 2019.
Corporate Restructuring Completed in January 2019: Selecta completed a corporate restructuring that reduced the company’s workforce by 36 percent as of January 3, 2019. This reduction, coupled with a re-prioritization of the company’s pipeline programs, is projected to
reduce the yearly cash burn by 19 percent.
Successfully Completed a $33.3 Million Public Offering; Providing Cash Runway into 1Q20: In January 2019, Selecta completed an underwritten public offering of 22,188,706 shares of its common stock, at a price to public of $1.50 per share, resulting in net proceeds to Selecta of $31.3 million, after deducting underwriting discounts and commissions.
Gonna put together a quick DD packet now. $SELB
Epic 1 year chart. Plenty of room to run
Yes been looking through all the filings the insiders gobbling up this many shares tells me they consider this bottom for what’s coming next $SELB
Nice man I still need to learn how to trade options, sounds like a good grab. $SELB
Boomin. Grabbed some 2.5 calls a few days ago. Insiders bought a TON between 1.5 and $3 so I expect this to make some consistent moves North from here. Could get going quick
Flying, let’s see if we can get $3.00 by EOD $SELB
Basing here at $2.40 pushing up now on the next intraday leg up. $SELB
Beat earnings by .10 and results were good for its recent study. Chart is a dream. Bought today. $SELB
Huge 200k buy EOD. Earnings tomorrow. Watch for breakout
Amazing.
PEPSI
here you go. a picture is worth a thousand words
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=BPTH&insttype=Stock
52 Week Range:
1.61 to 73.52
$5.00 to $73.00 in two days. Insane!
PEPSI
we shall see what happens. dinogreeves who called bpth at 5.00 before it soared to 73.00 in two days pm'd me on selb. said it's next. that's all i know
These types of stocks and I have seen a few of them lately can majorly breakout. From the News this a.m.
$SELB
PEPSI
https://seekingalpha.com/news/3441191-selecta-bio-21-percent-ahead-q4-report?fbclid=IwAR3QhmmnTRKabtIdTOXmtTDnzBCMyINMowaUDb3RzsYjNpK-eJ5beHOQRB8
Selecta Bio up 21% ahead of Q4 report
Mar. 8, 2019 10:36 AM ET|About: Selecta Biosciences (SELB)|By: Douglas W. House, SA News Editor
Micro cap Selecta Biosciences (SELB +21.2%) is up on a 4x surge in volume ahead of its Q4 and 2018 report before the open on March 15.
The surge in buying appears to be rippling from fellow tiny biotech Bio-Path Holdings which rocketed as high as 40-fold in about a week before retracing in response to positive data on prexigebersen.
See all stocks on the move »
TOP INSTITUTIONAL HOLDERS
Concentration of Current % Held
Top 10 Institutions: Ownership by top 10 institutions Top 20 Institutions: Ownership by top 20 institutions Top 50 Institutions: Ownership by top 50 institutions All: Ownership by all institutions
Low
Avg. Turnover Rating
Name
Shares Held
Position Value
Percentage of
Total Holdings
since 3/8/19
% Owned
of Shares
Outstanding Turnover
Rating
GLG Partners LP
3.7M $5,766,010 +17% 16.3% Moderate
Polaris Venture ...
2.8M $4,354,362 +13% 12.3% Low
TAS Partners, L.L.C.
2.1M $25,185,729 +10% 9.6% Low
OrbiMed ...
1.6M $4,200,310 +8% 7.0% Moderate
NanoDimension AG
1.1M $10,576,720 +5% 4.8% --
RUSNANO
810.7K $2,156,369 +4% 3.6% Low
BlackRock ...
799.2K $2,125,899 +4% 3.6% Low
Cautreels (Werner C)
612.5K $7,178,465 +3% 2.7% Low
Kennedy Capital ...
601.0K $1,598,559 +3% 2.7% Moderate
Invus Public ...
600.0K $1,596,000 +3% 2.7% Moderate
TOP MUTUAL FUND HOLDERS
Percentage of Outstanding Shares per Holdings Style (Top 10)
Index 4.9%
Growth 1.0%
International 0.8%
GARP 0.6%
Aggres. Gr. 0.5%
Core Growth 0.4%
Sector Specific 0.3%
Income Value 0.1%
Mixed Style 0.0%
Core Value 0.0%
Low
Avg. Turnover Rating
Name
Shares Held
Position Value
Percentage of
Total Holdings
since 3/8/19
% Owned
of Shares
Outstanding Investment
Style
iShares Russell ...
374.2K $744,636 +2% 1.7% Index
JPMorgan U.S. ...
234.0K $367,380 +1% 1.0% Growth
FCP OP Medical ...
173.0K $460,180 +1% 0.8% International
Vanguard ...
171.4K $269,137 +1% 0.8% Index
iShares Russell ...
157.6K $313,628 +1% 0.7% Index
Wasatch Ultra ...
108.2K $287,690 +1% 0.5% Aggres. Gr.
Fidelity ...
61.4K $96,417 0% 0.3% Index
VY JPMorgan ...
59.6K $158,536 0% 0.3% GARP
Fidelity Small ...
54.0K $277,483 0% 0.2% Index
JP Morgan Small ...
52.9K $83,053 0% 0.2% GARP
https://www.cnbc.com/quotes/?symbol=selb&qsearchterm=selb&tab=ownership
Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update
Date : 03/08/2019 @ 8:00AM
Source : GlobeNewswire Inc.
Stock : Selecta Biosciences, Inc. (SELB)
Quote : 2.57 0.54 (26.60%) @ 9:50AM
Selecta Biosciences to Report Fourth Quarter and Year End 2018 Financial Results and Provide Corporate Update
Print
Alert
SELECTA BIOSCIENCES INC (NASDAQ:SELB)
Intraday Stock Chart
Today : Friday 8 March 2019
Click Here for more SELECTA BIOSCIENCES INC Charts.
Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta”), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR (SVP Rapamycin), today announced that it will report its fourth quarter full year end 2018 financial results and provide a corporate update before the open of the U.S. financial markets on Friday, March 15, 2019.
At 8:30 a.m. ET that day, Selecta will host a conference call and live audio webcast to discuss the year end 2018 financial results and provide a corporate update. Investors and the public can access a live and archived webcast of this call via the Investors & Media section of the company’s website, http://selectabio.com. Individuals may also participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10127200.
About Selecta Biosciences, Inc.
Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance technology (ImmTOR) platform. Selecta plans to combine ImmTOR with a range of biologic therapies for rare and serious diseases that require new treatment options due to high immunogenicity. The company’s current proprietary pipeline includes ImmTOR-powered therapeutic enzyme and gene therapy product candidates. SEL-212, the company’s lead product candidate, is being developed to treat chronic refractory gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta’s proprietary gene therapy product candidates are in preclinical development for certain rare inborn errors of metabolism and incorporate ImmTOR with the goal of addressing barriers to repeat administration. Selecta is based in Watertown, Massachusetts. For more information, please visit http://selectabio.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing of future events. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to those set forth in the “Risk Factors” section of Selecta’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 8, 2018, and in other filings that Selecta makes with the SEC. In addition, any forward-looking statements included in this press release represent Selecta’s views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Selecta specifically disclaims any obligation to update any forward-looking statements included in this press release.
Investors:
Sarah McCabe
Stern Investor Relations, Inc.
+1-212-362-1200
sarah@sternir.com
Media:
Lauren Tortorete
Spectrum Science Communications, Inc.
+1-212-468-5379
ltortorete@spectrumscience.com
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
85
|
Created
|
01/08/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |